Sanofi (EPA:SAN) PT Set at €95.00 by Goldman Sachs Group
Goldman Sachs Group set a €95.00 ($110.47) price target on Sanofi (EPA:SAN) in a report issued on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.
Several other equities analysts also recently issued reports on SAN. JPMorgan Chase & Co. set a €81.00 ($94.19) price objective on shares of Sanofi and gave the company a neutral rating in a research note on Friday, November 1st. Barclays set a €80.00 ($93.02) target price on shares of Sanofi and gave the stock a neutral rating in a research note on Friday, November 22nd. UBS Group set a €89.50 ($104.07) price target on Sanofi and gave the company a buy rating in a report on Friday, November 22nd. Jefferies Financial Group set a €95.00 ($110.47) price target on Sanofi and gave the stock a buy rating in a research note on Wednesday, November 27th. Finally, Kepler Capital Markets set a €88.00 ($102.33) price objective on Sanofi and gave the stock a buy rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. Sanofi has an average rating of Buy and an average target price of €89.81 ($104.43).
Shares of EPA SAN traded up €0.43 ($0.50) during midday trading on Thursday, reaching €83.56 ($97.16). 1,822,884 shares of the stock were exchanged, compared to its average volume of 3,050,000. The stock has a 50 day moving average price of €83.28 and a 200-day moving average price of €78.75. Sanofi has a 52-week low of €63.09 ($73.36) and a 52-week high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: Short Selling
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.